Completed PHASE1 INTERVENTIONAL 6-arm NCT03004339

Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test

A Phase 1 Randomized, Placebo and Active Comparator-controlled Trial, Double-blind for the IPs, Observer-blind for the Active Comparator, to Assess the Potency of SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment in a Psoriasis Plaque Test

Sponsor: Bioskin GmbH

Conditions Plaque Psoriasis

Interventions SOR007 Ointment 0.15% SOR007 Ointment 0.3% SOR007 Ointment 1.0% SOR007 Ointment 2.0% SOR007 Ointment Placebo Taclonex® Ointment

Updated 7 times since 2017 Last updated: Feb 11, 2019 Started: Aug 31, 2016 Primary completion: Feb 13, 2017 Completion: Feb 13, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Plaque Psoriasis, this trial is completed. The trial is conducted by Bioskin GmbH and has accumulated 7 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Mar 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Mar 2019 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bioskin GmbH
DFB Soria, LLC
US Biotest, Inc.

Data source: DFB Soria, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States
• College Station, United States